Skip to main content Presents the DayOne Acceleration Program Supported by Fondation Botnar

| News Presents the DayOne Acceleration Program Supported by Fondation Botnar


Seeking brilliant project ideas that, combined with digital technologies, healthcare expertise and entrepreneurial spirit, will help solve the health challenges and unmet needs of young people. Selected projects will receive up to 70,000 CHF in non-dilutive funding.

DayOne, the swiss innovation hub for precision medicine and digital health run by, is launching an acceleration program supported by Fondation Botnar. Applications are now open to project ideas improving the wellbeing and health of children and adolescents worldwide.

The acceleration program will include a tailor-made mentoring program, access to DayOne industry experts and collaborative workspace at the DayOne Lab. Selected projects will receive up to 70,000 CHF in non-dilutive funding. We are looking for brilliant ideas that, combined with digital technologies, healthcare expertise and entrepreneurial spirit, will help solve the health challenges and unmet needs of young people.

The program welcomes healthcare innovators, start-ups and entrepreneurs as well as intrapreneurs willing to accelerate their project outside of their corporate environment.

We at DayOne believe that healthcare is moving from the hospital to the living room and changing from a sick repair system to a health system. Therefore, Fondation Botnar through the DayOne Acceleration program is reaching out to healthcare innovators who are passionate about developing new approaches to improve the wellbeing and health of children and adolescents around the world in any setting. The solutions should have a strong impact delivering health outcomes, while being cost-efficient, scalable and sustainable.

The program will support teams and individuals who strive to:

  • go beyond research and create minimal viable healthcare products and services
  • target health Issues with a special focus on pediatrics and/or adolescents
  • enable frontline work to deliver better health outcomes
  • lower the healthcare costs and be scalable and therefore making their solution suitable for all markets including in emerging countries.

The solutions should embrace a human centric approach focusing on young people and make appropriate use of Digital Technologies (Mobile Apps, AI, Blockchain etc.)

Participants will have the opportunity to drive their project idea forward in a collaborative way engaging with the healthcare innovation ecosystem of the Basel Region. Applicants should therefore be willing to be present in the Basel region and be able to dedicate sufficient personal time to execute on their idea during the six-month period of the DayOne Acceleration Program.

The deadline for the initial application is July 31st.

An initial selection of projects will be made in early August. The selected projects will participate at the DayOne conference on September 11th in Basel where they will receive valuable feedback on their project idea from healthcare innovation experts. They will then have 3 weeks to complete a final application by September 30 th. The formal acceleration program will start no later than January 14 th 2019 and be for a period of 6 months.

Registration and more information

Get involved now, fill out the application.
For more Information, please see our FAQs.

About Fondation Botnar

Fondation Botnar is a charitable foundation established with the core purpose to support children’s basic needs throughout the world. It was founded in Basel in 2003 to continue the philanthropic work of the Botnar family. Its focus is health, nutrition and education.

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

Meteoblue constantly presents new developments

The meteoblue weather service based in Basel has developed a weather map widget that can be embedded in any website....
Read More

Lonza manufactures coronavirus vaccine for Moderna

Lonza plans to start production of Moderna’s coronavirus vaccine in Switzerland before the end of the year. Moderna published the...
Read More

Synendos raises 20 million Swiss francs

Synendos Therapeutics has concluded a Series A financing round, raising 20 million Swiss francs. The Basel biotech will use the...
Read More

ChemAxon establishes subsidiary in Basel

ChemAxon develops software for application in the chemicals and biopharma industries. Now, the Hungarian company has established a subsidiary in...
Read More

DSM strengthens the Basel Area life sciences cluster

The global nutrition and health corporation Royal DSM is establishing a new innovation center at the headquarters of Nutritional Products...
Read More

Canton of Jura looking towards robotics

The canton of Jura has for quite some time been a hub for the precision industry. Now, however, companies such...
Read More

Novartis agrees cooperation to fight Covid-19

A collaboration between Molecular Partners and Novartis has been announced. Molecular Partners will be responsible for the Phase 1 trials...
Read More

An intense and ambitious year for the Jura site of the Switzerland Innovation Park Basel Area

Despite the coronavirus pandemic, which has delayed some projects, the Jura site of the Switzerland Innovation Park Basel Area has...
Read More

VectivBio secures investments totaling 110 million dollars

The Basel-based biotechnology firm VectivBio has received a capital injection of 110 million US dollars from both new and existing...
Read More

Polyphor receives up to 18 million dollars for development of antibiotics

The Allschwil-based company Polyphor has received a second funding award from the global consortium CARB-X to combat antimicrobial resistance. Polyphor...
Read More

DayOne Accelerator applications open

We are excited to announce the opening of the call for the DayOne Accelerator, now in its 3rd year!
Read More

Matériaux Sabag printing concrete elements

The Jura-based company Matériaux Sabag is now using a 3D printing solution to produce its concrete elements. This approach allows...
Read More

Monte Rosa Therapeutics banks 96 million US dollars

The Basel-based biotechnology firm Monte Rosa Therapeutics has raised a total of 96 million US dollars after closing a successful...
Read More

Roche launches new coronavirus antibody test

Roche is launching on the market a new antibody test to determine coronavirus infections. This should help with the development...
Read More

Investors see great potential in Polyneuron

The Basel-based company Polyneuron Pharmaceuticals extended its Series A funding round and has now raised a total of 36.5 million...
Read More

Lonza set to manufacture coronavirus drug for Humanigen

The Basel-based pharmaceutical supplier Lonza is supporting the US firm Humanigen in the development of a potential coronavirus therapeutic. Lonza...
Read More

Startups from the Basel Area ranked among the best

Startups from the Basel Area have been ranked highly in the TOP 100 Swiss Startup Award by Venturelab. The medtech...
Read More

Roche testing for coronavirus and flu simultaneously

The U.S. Food and Drug Administration has given the Basel-based life sciences company Roche authorization to use a test that...
Read More

Hengrui Medicine sets up clinical research and development in Basel

The Chinese life sciences company Hengrui Medicine is establishing a Swiss subsidiary in Basel. The European hub for clinical research...
Read More

Polyphor awarded exclusive licensing agreement for China

The Basel Area-based company Polyphor has signed an exclusive licensing agreement with Fosun Pharma in China. Fosun Pharma will lead...
Read More

Do you have a question? We'd like to hear from you.